BPC-157

Overview

BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide: a chain of fifteen amino acids. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The peptide is derived from a fragment of a larger protective protein found naturally in human gastric juice. That parent protein was isolated in the early 1990s by Sikiric and colleagues at the University of Zagreb. The number 157 marks where this fragment sat within that original screening programme.

One property sets BPC-157 apart from most linear peptides: its stability. Linear peptides usually break down fast in the acidic, enzyme-rich environment of the stomach. BPC-157 stays intact there strikingly long. That stability is attributed to three consecutive proline residues at the start of the chain. Proline gives the chain a rigid, compact shape. That shape makes the peptide harder to cleave for proteases, the enzymes that break proteins down.

Almost everything known about BPC-157 comes from preclinical work. Across cell systems and rodent models, a substantial and internally consistent body of literature has built up over more than three decades. A large share of it, however, comes from a single research group. Independent replication by other laboratories is therefore the obvious next step, and exactly where new work would count most.

Human research, by contrast, is sparse. Three small, uncontrolled pilot studies have been published, with 2, 16 and 12 participants respectively. None was randomised or placebo-controlled. A registered phase I study was also terminated without its results appearing. Controlled human trials are still entirely absent. The preclinical signal is scientifically interesting and mechanistically coherent; what is not yet established is what it means for humans. BPC-157 has not been approved for human use by any regulatory authority.

Mechanism of action

BPC-157 has no single defined receptor as its target. The research points instead to several partly overlapping signalling pathways tied to tissue protection and repair. One point stands out: after three decades of research, no high-affinity receptor has been identified. The molecular target formally remains unknown. That makes the mechanism both intriguing and incompletely understood.

Angiogenesis and vascular signalling

• Activation of the VEGFR2 pathway, which drives the formation of new blood vessels (angiogenesis) at sites of tissue damage, as observed in animal models.
• Modulation of the nitric oxide (NO) system, including the enzyme eNOS, with effects on microvascular perfusion.
• Upregulation of heme oxygenase-1 (HO-1), an enzyme with antioxidant properties.

Cellular signalling and gene expression

• Modulation of the FAK-paxillin pathway, which organises cell migration and contributes to repair of the extracellular matrix, the structural scaffold between cells.
• Upregulation of the transcription factor Egr-1 and its regulatory partner NAB2. Transcription factors are proteins that determine which genes are read; in the literature, Egr-1 and NAB2 act as switch points in repair gene networks.
• Increased expression of growth factors, including VEGF, and dampening of pro-inflammatory signalling in animal models.

Stability and pharmacokinetics

• Unusual stability in gastric juice, attributed to the proline-rich structure at the start of the chain.
• A short half-life in blood. In independent pharmacokinetic work in rat and dog it was under 30 minutes, with rapid clearance via the kidneys and protein degradation. Half-life is the time it takes for blood concentration to fall by half.
• A striking contrast between that short half-life and biological effects in the literature that appear to persist much longer. This unexplained gap is an active area of mechanistic study.

Research findings

• Accelerated structural repair in musculoskeletal injury models
• Protection of the gastric lining against alcohol and NSAID-induced damage
• Support of intestinal integrity in bowel injury models
• Promotion of new blood vessel formation in animal models
• Modulation of inflammatory signalling across tissue types
• First independent pharmacokinetics (2022): half-life <30 min, IM bioavailability 14–51%

Musculoskeletal models

• Accelerated structural repair of tendon, ligament and muscle injuries was reported in rodent studies, alongside improved functional outcomes.
• Proposed mechanisms include Egr-1-driven activation of fibroblasts (connective-tissue cells), VEGF-mediated blood vessel formation and collagen synthesis.

Gastrointestinal models

• Protection of the gastric lining against damage from alcohol and NSAIDs (non-steroidal anti-inflammatory drugs) in animal models.
• Support of intestinal integrity and repair in models of bowel injury.

Vascular and systemic models

• Promotion of new blood vessel formation and modulation of inflammatory signalling in animal models.
• Cytoprotective effects described across a range of organs. Cytoprotection means protection of cells against damage.

Pharmacokinetics

• The first independent, regulatory-grade pharmacokinetic study appeared in 2022, in rat and beagle. It confirmed a half-life under 30 minutes, a linear relationship between dose and exposure, and an intramuscular bioavailability of 14 to 51 percent depending on species.

Human research

• The published human data consist of three small, uncontrolled pilot studies with 2, 16 and 12 participants. None were randomised or placebo-controlled. No serious adverse events were reported, but the numbers are too small to draw conclusions.

Research context

BPC-157 has been investigated primarily in in vitro systems and rodent models. The most recent independent analysis is a 2026 biopharmaceutical review. That review places the human evidence at the lowest tier of the evidence hierarchy: three uncontrolled pilot studies, without standardised preparations. The same review names two limitations on interpretation. The first is the heavy concentration of the primary literature in a single research group. The second is the absence of validated pharmacokinetic and formulation data.

At the same time, the preclinical foundation is broad and internally consistent. Since 2022, the first independent pharmacokinetic work outside the original group has appeared. BPC-157 thus sits in a recognisable middle ground: mechanistically rich, but clinically still largely unmapped. Large-scale controlled human trials are absent, and the compound has not been approved for clinical use by any regulatory authority.

Open questions

Evidence is concentrated in preclinical work; controlled human data remain absent.

• Randomised controlled human trials are missing. For clinical research groups, this is the most direct next step: a controlled study in a well-defined indication.
• The molecular target is unknown; after three decades, no receptor has been identified. For laboratories working on receptor deconvolution and target identification, this is an open and fundamental question.
• The gap between the short half-life and the longer-lasting biological effects is unexplained. Mechanistic work on the time course of gene expression and tissue distribution could begin to give direction here.
• Validated human pharmacokinetics and a standardised formulation are missing. Pharmaceutical work on formulation and bioanalytical methods is a precondition for any clinical step.
• The primary literature is heavily concentrated in a single group. Independent replication across diverse laboratories would substantially strengthen the preclinical foundation.

Research outlook

Independent replication of preclinical findings across diverse laboratories.

Identification of the molecular target and resolution of the gap between half-life and effect duration.

Validated human pharmacokinetics and a standardised, well-characterised formulation.

Controlled human studies in well-defined indications, with gastrointestinal and musculoskeletal contexts as the most substantiated starting points.

Scientific interest

Unusual molecular stability: the proline-rich structure that makes the peptide resistant to gastric acid, rare among linear peptides.

An unresolved molecular target: after three decades of research, no receptor has been identified, an open mechanistic question.

Gap between half-life and effect duration: the tension between a half-life of minutes and effects in the literature that appear to persist much longer.

Broad preclinical signal across tissue types: described in gastrointestinal, musculoskeletal and vascular animal models, as a basis for future controlled research.

Specifications

References

1. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. · Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS · Journal of Molecular Medicine · 2017
2. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. · Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research · 2019
3. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. · Sikiric P, Drmic D, Sever M, Klicek R, Blagaic AB, Tvrdeic A, Kralj T, Kovac KK, Vukojevic J, Siroglavic M, Gojkovic S, Krezic I, Pavlov KH, Rasic D, Mirkovic I, Kokot A, Skrtic A, Seiwerth S · Current Pharmaceutical Design · 2020
4. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. · Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Prtoric A, Zizek H, Durasin T, Dobric I, Staresinic M, Strbe S, Knezevic M, Sola M, Kokot A, Sever M, Lovric E, Skrtic A, Blagaic AB, Sikiric P · Frontiers in Pharmacology · 2021
5. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. · He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q · Frontiers in Pharmacology · 2022
6. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. · Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, Popa MD, Iurciuc S, Muresan CO, Enache A · Pharmaceutics · 2026

Availability

In stock · Batch PEP-BPC-2026-01 · HPLC 98.96 % · released 31 Aug 2026

• BPC-157 10 mg · product page with price and batch CoA